Literature DB >> 15477921

Anti-cyclic citrullinated antibodies: complementary to IgM rheumatoid factor in the early diagnosis of rheumatoid arthritis.

Kamal Solanki1, Myfanwy Spellerberg, Peter Chapman, Peter Moller, John O'Donnell.   

Abstract

AIMS: To compare the diagnostic sensitivity of anti-cyclic citrullinated (CCP) antibodies and rheumatoid factor (RF) in rheumatoid arthritis (RA) within a general hospital setting.
METHOD: Using the American College of Rheumatology (ACR) classification criteria as a gold standard, the frequency of RF and anti-CCP antibody positivity was compared between two groups of RA patients: those with disease duration less than 2 years (early RA, ERA) and those with disease duration more than 2 years (late RA, LRA).
RESULTS: In ERA, the diagnostic sensitivity of RF and anti-CCP antibodies was 57% and 79% respectively. In LRA, it was 81% and 84% respectively.
CONCLUSION: Anti-CCP antibodies are 20% more sensitivity than RF in the diagnosis of early RA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477921

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  3 in total

1.  Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF.

Authors:  I G Silveira; R W Burlingame; C A von Mühlen; A L Bender; H L Staub
Journal:  Clin Rheumatol       Date:  2007-04-05       Impact factor: 2.980

Review 2.  Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.

Authors:  J Avouac; L Gossec; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

3.  A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis.

Authors:  Lisiane Maria Enriconi dos Anjos; Ivanio Alves Pereira; Eleonora d 'Orsi; Andrea Piette Seaman; Rufus Watson Burlingame; Edelton Flavio Morato
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.